• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Remissions after long-term use of romiplostim for immune thrombocytopenia.

作者信息

Marshall Ariela L, Scarpone Roberta, De Greef Melanie, Bird Robert, Kuter David J

机构信息

Division of Hematology, Mayo Clinic. USA

Center for Hematology, Massachusetts General Hospital, USA.

出版信息

Haematologica. 2016 Dec;101(12):e476-e478. doi: 10.3324/haematol.2016.151886. Epub 2016 Sep 1.

DOI:10.3324/haematol.2016.151886
PMID:27587382
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5479599/
Abstract
摘要

相似文献

1
Remissions after long-term use of romiplostim for immune thrombocytopenia.长期使用罗米司亭治疗免疫性血小板减少症后的缓解情况。
Haematologica. 2016 Dec;101(12):e476-e478. doi: 10.3324/haematol.2016.151886. Epub 2016 Sep 1.
2
Treatment of chronic immune thrombocytopenia in children with romiplostim.用罗米司亭治疗儿童慢性免疫性血小板减少症。
Lancet. 2016 Jul 2;388(10039):4-6. doi: 10.1016/S0140-6736(16)00589-4. Epub 2016 Apr 18.
3
Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.评论：血小板生成素受体激动剂（罗米司亭）在因母亲免疫性血小板减少症导致的新生儿自身免疫性血小板减少症中的应用。
Pediatr Blood Cancer. 2019 Jun;66(6):e27706. doi: 10.1002/pbc.27706. Epub 2019 Mar 11.
4
Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.血小板生成素受体激动剂罗米司亭对自身免疫性血小板减少性紫癜的挽救治疗揭示了非霍奇金淋巴瘤。
Br J Haematol. 2012 Jan;156(1):145-7. doi: 10.1111/j.1365-2141.2011.08825.x. Epub 2011 Aug 16.
5
Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura.一名免疫性血小板减少性紫癜患者接受罗米司亭治疗后血小板功能恢复
Br J Haematol. 2010 May;149(4):625-8. doi: 10.1111/j.1365-2141.2010.08092.x. Epub 2010 Feb 8.
6
Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.罗米司亭在艾曲泊帕耐药或不耐受的免疫性血小板减少症患者中的安全性和有效性。
Br J Haematol. 2013 Oct;163(2):286-9. doi: 10.1111/bjh.12483. Epub 2013 Jul 17.
7
Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.血小板生成素受体激动剂对免疫性血小板减少症患者静脉注射免疫球蛋白使用情况的影响。
Transfusion. 2016 Jan;56(1):73-9. doi: 10.1111/trf.13336. Epub 2015 Sep 24.
8
Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim.对于一名正在使用罗米司亭治疗的慢性免疫性血小板减少性紫癜患者，行脾切除术后反应性血小板增多症的血小板单采术
J Clin Apher. 2013 Aug;28(4):321-4. doi: 10.1002/jca.21254. Epub 2013 Mar 1.
9
The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.利妥昔单抗与血小板生成素受体激动剂联合治疗高危难治性免疫性血小板减少症
Blood Transfus. 2015 Oct;13(4):694-5. doi: 10.2450/2015.0325-14. Epub 2015 Apr 21.
10
Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy.妊娠合并慢性免疫性血小板减少性紫癜应用血小板生成素模拟物治疗。
Obstet Gynecol. 2013 Aug;122(2 Pt 2):483-485. doi: 10.1097/AOG.0b013e31828d5b56.

引用本文的文献

1
Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey.血小板生成素，血小板生成的主要调节因子：从神话到理性，三十年的历程
Biomolecules. 2024 Apr 18;14(4):489. doi: 10.3390/biom14040489.
2
Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia.二线治疗方案在成人慢性免疫性血小板减少症中的成本效益。
Am J Hematol. 2023 Jan;98(1):122-130. doi: 10.1002/ajh.26497. Epub 2022 Feb 24.
3
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.免疫性血小板减少症中血小板生成素受体激动剂的二线治疗：基于意大利德尔菲法的共识推荐
Ther Adv Hematol. 2021 Oct 9;12:20406207211048361. doi: 10.1177/20406207211048361. eCollection 2021.
4
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.原发性免疫性血小板减少症中血小板生成素受体激动剂的减量：基于兰德/加州大学洛杉矶分校改良德尔菲专家小组法的专家共识
Res Pract Thromb Haemost. 2020 Dec 8;5(1):69-80. doi: 10.1002/rth2.12457. eCollection 2021 Jan.
5
Updated international consensus report on the investigation and management of primary immune thrombocytopenia.更新的原发性免疫性血小板减少症的调查和管理国际共识报告。
Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.
6
Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.在常规临床实践中用罗米司亭治疗原发免疫性血小板减少症（ITP）：来自英国 ITP 注册研究的回顾性研究。
Eur J Haematol. 2019 May;102(5):416-423. doi: 10.1111/ejh.13221. Epub 2019 Mar 7.

本文引用的文献

1
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.罗米司亭治疗原发性免疫性血小板减少症的缓解及血小板反应：一项2期研究的最终结果
Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5.
2
Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.成人原发性免疫性血小板减少症中对血小板生成素受体激动剂有反应的患者停用罗米司亭的可行性：真实临床实践中的一项观察性回顾报告
Hematol Rep. 2015 Feb 24;7(1):5673. doi: 10.4081/hr.2015.5673.
3
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.在原发性免疫性血小板减少症患者完全缓解后成功停用艾曲泊帕。
Am J Hematol. 2015 Mar;90(3):E40-3. doi: 10.1002/ajh.23900. Epub 2015 Jan 16.
4
The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study.促血小板生成素受体激动剂的临时使用可能会诱导成人慢性免疫性血小板减少症的长期缓解。一项法国观察性研究的结果。
Br J Haematol. 2014 Jun;165(6):865-9. doi: 10.1111/bjh.12888. Epub 2014 Apr 12.
5
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.慢性免疫性血小板减少症患者使用罗米司亭的长期治疗：安全性和疗效。
Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22.
6
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.血小板生成素治疗的免疫性血小板减少症（ITP）患者中的纤维增生活性。
Br J Haematol. 2011 Oct;155(2):248-55. doi: 10.1111/j.1365-2141.2011.08845.x. Epub 2011 Sep 9.
7
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.美国血液学会 2011 年免疫性血小板减少症循证实践指南。
Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984. Epub 2011 Feb 16.
8
Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.慢性免疫性血小板减少症的发病机制：血小板破坏增加和/或血小板生成减少。
Br J Haematol. 2009 Sep;146(6):585-96. doi: 10.1111/j.1365-2141.2009.07717.x. Epub 2009 May 14.
9
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.成人及儿童免疫性血小板减少性紫癜术语、定义及疗效标准的标准化：国际工作组报告
Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
10
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP.罗米司亭长期治疗慢性免疫性血小板减少症血小板减少患者的安全性和有效性。
Blood. 2009 Mar 5;113(10):2161-71. doi: 10.1182/blood-2008-04-150078. Epub 2008 Nov 3.